Pharmaceuticals

Latest KFF Health News Stories

The FTC Escalates Biden’s Fight Against Drug Prices

KFF Health News Original

It’s daggers out at the Federal Trade Commission in its fight against anticompetitive practices in health care. This past year, it has issued more stringent guidelines to block and discourage hospital mergers, and it investigated practices by middlemen in the drug supply chain. Now drug manufacturers themselves are in the agency’s crosshairs. In November, the FTC challenged the validity of more […]

Alex Azar’s Unusual Spin Through the Revolving Door

KFF Health News Original

Washington’s infamous revolving door took an unusual turn for former Health and Human Services secretary Alex Azar. Azar spent about a decade with pharmaceutical giant Eli Lilly and Co. before coming to the nation’s capital to lead HHS in the Trump administration. But in September 2020, just a couple of months before former president Donald […]

KFF Health News' 'What the Health?': 2023 Is a Wrap

Podcast

2023 was another busy year in health care. As the covid-19 pandemic waned, policymakers looked anew at long-standing obstacles to obtaining and paying for care in the nation’s health care system. Meanwhile, abortion has continued to be an issue in much of the nation, as states respond to the Supreme Court’s 2022 decision overturning the constitutional right to the procedure. This week, Rachel Cohrs of Stat, Sandhya Raman of CQ Roll Call, and Joanne Kenen of Johns Hopkins University and Politico Magazine join KFF Health News chief Washington correspondent Julie Rovner to discuss these issues and wrap up the year in health. Also this week, Rovner interviews KFF Health News’ Jordan Rau about his joint KFF Health News-New York Times series “Dying Broke.”

The Year in Opioid Settlements: 5 Things You Need to Know

KFF Health News Original

In the past year, opioid settlement money has gone from an emerging funding stream for which people had lofty but uncertain aspirations to a coveted pot of billions being invested in remediation efforts. Here are some important and evolving factors to watch going forward.

The Market for Biosimilars Is Funky. The Industry Thinks PBMs Are To Blame

KFF Health News Original

Over the past year there’s been movement to rein in the three big PBMs, which face little regulation though they help set drug prices and drug choices for 80 percent of Americans and their doctors. The House voted Dec. 11, 320-71, for legislation that would require the PBMs to change some of the ways they […]

Millions of Dollars Flow From Pharma to Patient Advocacy Groups

KFF Health News Original

Pharma money is all over the place — in universities, companies doing continuing medical education for doctors and in prominent patient advocacy organizations that are household names across America. Public Citizen, a consumer advocacy nonprofit, reports today that between 2010 and 2022, the drug industry’s main lobbying group and member companies provided at least $6 […]